Nitric Oxide Metabolites and Lung Cancer Incidence: A Matched Case-Control Study Nested in the ESTHER Cohort

Table 4

Associations of a nitrite/nitrate concentration with lung cancer incidence in a sensitivity analyses excluding lung cancer cases which occurred in the first 5 years of follow-up, the ESTHER study (2000-2014).

	Nitrite/nitrate levels (μmol/mmol creatinine)		Main model^a; OR (95% CI)	Sensitivity model 1^b; OR (95% CI)	Sensitivity model 2^c; OR (95% CI)
Quintile 1	<67.7	37/101	Ref.	Ref.	Ref.
Quintile 2	67.7 - <97.4	29/101	0.88 (0.60-1.29)	0.88 (0.602-1.29)	0.88 (0.60-1.29)
Quintile 3	97.4 - <133.7	31/101	0.95 (0.65-1.38)	0.95 (0.66-1.39)	0.95 (0.66-1.39)
Quintile 4	133.7 - <188.8	26/101	0.81 (0.55-1.18)	0.80 (0.55-1.18)	0.81 (0.55-1.19)
Quintile 5	≥188.77	45/100	1.36 (0.97-1.92)	1.36 (0.97-1.92)	1.34 (0.95-1.90)

^aAdjusted for body mass index (BMI), education, family history of lung cancer, asthma, physical activity, and vegetable and meat consumption frequency. In addition, potential confounding by the following factors was controlled by matching age, sex, smoking status, and pack-years of smoking. ^bAdjusted for variables of the main model+C-reactive protein (CRP). In addition, potential confounding by the following factors was controlled by matching age, sex, smoking status, and pack-years of smoking. ^cAdjusted for variables of the main model+8-isoprostane. In addition, potential confounding by the following factors was controlled by matching age, sex, smoking status, and pack-years of smoking.